Medical/Pharmaceuticals

GC Genome enables the prognosis prediction and targeted treatment in breast cancer patients

YONGIN, South Korea, July 26, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a new study in Journal of the National Cancer Institute (JNCI), shedding light on the remarkable potential of utilizing circulating tumor DNA (ctDNA) copy n...

2023-07-27 08:53 1223

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China

Everest transforms into a commercial-stage innovative biopharmaceutical company SHANGHAI, July 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicin...

2023-07-27 08:10 2158

SK Inc.'s board of directors declares an interim dividend of KRW 1,500 per share

* The first interim dividend payout after Articles of Incorporation were amended to enable investors to invest after checking dividend amount * Shareholders of record as of August 10, 2023 will receive dividend payout  SEOUL, South Korea, July 27, 2023 /PRNewswire/ -- SK Inc. announced that it...

2023-07-27 08:00 1919

YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023

Total revenues increase by 36.3% year-over-year; gross margin improves to 77.7%; balance sheet remains robust Company's PIKA rabies vaccine approved for Phase III clinical trials in Singapore, the Philippines, and Pakistan; interim results expected early next year GAITHERSBURG, Md., July 27, 20...

2023-07-27 05:00 4398

Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development

* Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in patients with squamous non-small cell lung cancer and patients with genetic aberrations in HER3 signaling * Hummingbird Bioscience has identified genetic signatures that are predictive of response t...

2023-07-27 04:00 2000

CartiHeal Announces First Commercial Implantation of Agili-C™ in the US

KFAR SABA, Israel, July 26, 2023 /PRNewswire/ -- CartiHeal Ltd. , developer of implants for the treatment of cartilage and osteochondral defects in arthritic and non-arthritic knee-joints, today announced its first commercial implantation of Agili-C in the US by Dr. Ken...

2023-07-26 21:04 1729

PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

DAEJEON, South Korea, July 26, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Compa...

2023-07-26 20:00 1679

Philips Future Health Index 2023 Report: APAC's healthcare sector embracing new care delivery model to tackle financial pressures and staff shortages

* Largest global survey of its kind finds investment in smart and connected digital health technologies and expansion of virtual care towards new models of care are top priorities for the region. * Healthcare professionals in APAC are counting on new care delivery models to enable better pati...

2023-07-26 16:05 2138

Samsung Biologics Reports Second Quarter 2023 Financial Results

* Recorded Q2'23 consolidated revenue of KRW 866.2 billion * Recorded Q2'23 consolidated operating profit of KRW 253.4 billion * Achieved record-high semi-annual revenue exceeding KRW 1,587.1 billion * Strong growth sustained with successful contract wins and full completion of Plant 4 set ...

2023-07-26 15:23 1968

World's first*1 report: A potential effectiveness of Plasmacluster Technology that may induce brain activation

Validation of the mechanism of its enhancing effect on human work performance by measuring brain function *2 OSAKA, Japan, July 26, 2023 /PRNewswire/ -- Sharp Corporation conducted collaborative research on its Plasmacluster technology, with Dr.Goichi Hagiwara , Associate Professor, Faculty of Hu...

2023-07-26 14:15 1743

Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023

SHANGHAI, July 25, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical trial data from phase I/II study for advanced solid tumor of Nectin-4-targeting ADC (9MW2821), and phase III study of Long-Acting Recombinant Hu...

2023-07-26 00:00 1882

Alma, a Sisram Medical Company, Announces the Launch of Alma Veil™ for the U.S. Market

HONG KONG and CHICAGO, July 25, 2023 /PRNewswire/ -- Alma, a global leader in the energy-based medical and aesthetic solutions industry, proudly announces the commercial availability of Alma Veil™. This advanced, dual-wavelength vascular laser workstation establishes a new standard in excellence ...

2023-07-25 22:10 2089

Fapon Launches the Most Efficient Chemiluminescence Immunoassay Analyzer to Date with Throughput of 900 T/h

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Fapon, a global leading life sciences company, has announced the launch of its latest chemiluminescence immunoassay system Shine i8000/9000 to global markets at the 2023 AACC exhibition. The high-speed and fully automated analyzer has an ultra-high ...

2023-07-25 20:07 1716

HaemaLogiX and Peter MacCallum Cancer Centre Announce Myeloma CAR-T Phase I Clinical Trial Agreement

* HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's CAR-T cell therapy in patients with kappa-type myeloma * The agreement is the culmination of previous preclinical research collaboration b...

2023-07-25 19:30 1302

RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal

YANTAI, China, July 25, 2023 /PRNewswire/ -- RemeGen Co., Ltd.  ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, has announced that their Phase II clinical study of telitacicept (RC18) for the treatment of ...

2023-07-25 16:00 1761

Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023

TAIPEI, July 25, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company has been selected for a late-breaking oral presentation on the positive primary outcomes of its aderamastat (FP-025) Phase 2 proof-of-concept allergic asthma study at the Euro...

2023-07-25 15:19 1881

Duopharma Biotech Applauded by Frost & Sullivan for Providing Innovative Healthcare Solutions in the Malaysian Market

Duopharma Biotech is a worldwide pioneer in the research and development of halal pharmaceuticals. SAN ANTONIO, July 25, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the Malaysian halal pharmaceutical industry and, based on its findings, recognizesDuopharma Biotech Berhad (Duopharma...

2023-07-25 14:00 1627

Clinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Science

HANGZHOU and SHAOXING, China, July 25, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Shanghai Public Health Clinical Center presented clinical results of ASC22 (Envafolimab) in combination with Chidamide for functional cure of human immunodeficiency virus...

2023-07-25 08:10 2244

Fapon to Showcase Innovative Diagnostic and Biopharma Solutions at 2023 AACC Expo

ANAHEIM, Calif., July 24, 2023 /PRNewswire/ -- Fapon, a leading life science company, will showcase its latest innovations in in-vitro diagnostic and biopharma solutions at the 2023 American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo fromJuly 25 to 27. At t...

2023-07-24 21:58 2005

Clarity reaches 50% recruitment milestone for Phase II SABRE prostate cancer trial

SYDNEY, July 24, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the Phas...

2023-07-24 21:02 1821
1 ... 171172173174175176177 ... 614